WGU D116 ADVANCED PHARMACOLOGY OA AND PRE
ASSESSMENT EXAM ACTUAL EXAM COMPLETE 200 QUESTIONS
WITH DETAILED VERIFIED ANSWERS AND RATIONALES (100%
CORRECT ANSWERS) /ALEREADY GRADED A+
1|Page
,WGU D116 ADVANCED PHARMACOLOGY
OA AND PRE-ASSESSMENT EXAMINATION
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Q1. A patient receives a drug intravenously and the plasma concentration curve shows an
immediate peak followed by a steady decline. Which pharmacokinetic parameter is best illustrated
by this profile?
A. First-pass metabolism
B. Bioavailability of 100%
C. Enterohepatic recirculation
D. Zero-order elimination
Correct Answer: B. Bioavailability of 100%
Rationale: Intravenous administration bypasses absorption barriers and hepatic first-pass
metabolism, delivering the entire dose directly into systemic circulation. This results in 100%
bioavailability. First-pass metabolism applies to orally administered drugs, while enterohepatic
recirculation would show secondary peaks. Zero-order elimination would show a linear decline
rather than the exponential curve typically seen.
Q2. A drug is administered orally and only 30% of the dose reaches systemic circulation
unchanged. The remaining 70% is primarily lost through which mechanism?
A. Renal tubular secretion
B. Hepatic first-pass metabolism
C. Plasma protein binding
D. Biliary excretion
Correct Answer: B. Hepatic first-pass metabolism
Rationale: After oral absorption, drugs travel via the portal vein to the liver before entering
systemic circulation. The liver metabolizes a portion of the drug during this first pass, reducing
bioavailability. Renal secretion and biliary excretion occur after the drug has already reached
systemic circulation. Plasma protein binding affects distribution, not initial bioavailability.
2|Page
, Q3. A patient with a serum creatinine of 3.2 mg/dL is prescribed a drug that is 90% renally
eliminated. Which pharmacokinetic parameter will most significantly affect dosing?
A. Volume of distribution
B. Protein binding
C. Clearance
D. Absorption rate
Correct Answer: C. Clearance
Rationale: Renal impairment reduces the clearance of drugs eliminated primarily by the kidneys.
Clearance determines the maintenance dose required to achieve steady-state concentrations. While
volume of distribution affects loading dose and protein binding may influence free drug levels,
clearance is the primary determinant of dosing adjustments in renal failure.
Q4. A drug has a therapeutic index of 2. What does this value indicate about the drug?
A. It has a wide margin of safety
B. It requires careful monitoring of plasma levels
C. It is safe for over-the-counter use
D. It has no adverse effects
Correct Answer: B. It requires careful monitoring of plasma levels
Rationale: A therapeutic index of 2 is very low, indicating a narrow margin between therapeutic
and toxic doses. Drugs with narrow therapeutic indices (e.g., digoxin, lithium, warfarin) require
therapeutic drug monitoring to avoid toxicity. A wide therapeutic index would be indicated by a
much higher ratio.
Q5. Which statement accurately describes the relationship between affinity and intrinsic
activity?
A. Affinity is the ability to bind a receptor; intrinsic activity is the ability to activate it
B. Affinity determines potency; intrinsic activity determines clearance
C. Affinity is only relevant for antagonists; intrinsic activity only for agonists
D. Affinity and intrinsic activity are synonymous terms
Correct Answer: A. Affinity is the ability to bind a receptor; intrinsic activity is the ability to
activate it
Rationale: Affinity refers to the strength of drug-receptor binding, while intrinsic activity
(efficacy) describes the drug's ability to produce a response after binding. A full agonist has both
high affinity and high intrinsic activity. An antagonist has affinity but zero intrinsic activity. Partial
agonists have affinity but lower intrinsic activity than full agonists.
3|Page
, Q6. A patient taking warfarin (a CYP2C9 substrate) is prescribed amiodarone (a CYP2C9
inhibitor). What is the expected clinical consequence?
A. Decreased warfarin effect
B. Increased risk of bleeding
C. No significant interaction
D. Warfarin toxicity is unlikely
Correct Answer: B. Increased risk of bleeding
Rationale: Amiodarone inhibits CYP2C9, which metabolizes warfarin. Inhibition of this enzyme
reduces warfarin metabolism, leading to increased plasma warfarin concentrations and elevated
INR. This significantly increases bleeding risk. The warfarin dose would typically need to be reduced.
Q7. Which route of administration completely bypasses first-pass metabolism?
A. Oral
B. Rectal
C. Sublingual
D. Enteral
Correct Answer: C. Sublingual
Rationale: Sublingual administration allows drugs to be absorbed directly into the systemic
circulation through the venous drainage of the oral mucosa, bypassing the portal circulation and
hepatic first-pass metabolism. Oral and enteral routes are subject to first-pass effects. Rectal
absorption is partially subject to first-pass metabolism.
Q8. A drug that binds to a receptor and produces a submaximal response even at full receptor
occupancy is classified as:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B. Partial agonist
Rationale: A partial agonist has affinity for the receptor but lower intrinsic activity than a full
agonist, producing a submaximal response even when all receptors are occupied. A full agonist
produces maximal response. An antagonist produces no response. An inverse agonist produces
effects opposite to those of an agonist.
Q9. A patient is a CYP2D6 poor metabolizer. How would this affect codeine analgesia?
A. Enhanced analgesia
B. No analgesia
4|Page
ASSESSMENT EXAM ACTUAL EXAM COMPLETE 200 QUESTIONS
WITH DETAILED VERIFIED ANSWERS AND RATIONALES (100%
CORRECT ANSWERS) /ALEREADY GRADED A+
1|Page
,WGU D116 ADVANCED PHARMACOLOGY
OA AND PRE-ASSESSMENT EXAMINATION
2026/2027 Examination
Total Questions: 200
Instructions:
• Answer all questions.
• Select the single best answer.
• Each question has four answer choices: A, B, C, and D.
• Select only ONE answer for each question.
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Q1. A patient receives a drug intravenously and the plasma concentration curve shows an
immediate peak followed by a steady decline. Which pharmacokinetic parameter is best illustrated
by this profile?
A. First-pass metabolism
B. Bioavailability of 100%
C. Enterohepatic recirculation
D. Zero-order elimination
Correct Answer: B. Bioavailability of 100%
Rationale: Intravenous administration bypasses absorption barriers and hepatic first-pass
metabolism, delivering the entire dose directly into systemic circulation. This results in 100%
bioavailability. First-pass metabolism applies to orally administered drugs, while enterohepatic
recirculation would show secondary peaks. Zero-order elimination would show a linear decline
rather than the exponential curve typically seen.
Q2. A drug is administered orally and only 30% of the dose reaches systemic circulation
unchanged. The remaining 70% is primarily lost through which mechanism?
A. Renal tubular secretion
B. Hepatic first-pass metabolism
C. Plasma protein binding
D. Biliary excretion
Correct Answer: B. Hepatic first-pass metabolism
Rationale: After oral absorption, drugs travel via the portal vein to the liver before entering
systemic circulation. The liver metabolizes a portion of the drug during this first pass, reducing
bioavailability. Renal secretion and biliary excretion occur after the drug has already reached
systemic circulation. Plasma protein binding affects distribution, not initial bioavailability.
2|Page
, Q3. A patient with a serum creatinine of 3.2 mg/dL is prescribed a drug that is 90% renally
eliminated. Which pharmacokinetic parameter will most significantly affect dosing?
A. Volume of distribution
B. Protein binding
C. Clearance
D. Absorption rate
Correct Answer: C. Clearance
Rationale: Renal impairment reduces the clearance of drugs eliminated primarily by the kidneys.
Clearance determines the maintenance dose required to achieve steady-state concentrations. While
volume of distribution affects loading dose and protein binding may influence free drug levels,
clearance is the primary determinant of dosing adjustments in renal failure.
Q4. A drug has a therapeutic index of 2. What does this value indicate about the drug?
A. It has a wide margin of safety
B. It requires careful monitoring of plasma levels
C. It is safe for over-the-counter use
D. It has no adverse effects
Correct Answer: B. It requires careful monitoring of plasma levels
Rationale: A therapeutic index of 2 is very low, indicating a narrow margin between therapeutic
and toxic doses. Drugs with narrow therapeutic indices (e.g., digoxin, lithium, warfarin) require
therapeutic drug monitoring to avoid toxicity. A wide therapeutic index would be indicated by a
much higher ratio.
Q5. Which statement accurately describes the relationship between affinity and intrinsic
activity?
A. Affinity is the ability to bind a receptor; intrinsic activity is the ability to activate it
B. Affinity determines potency; intrinsic activity determines clearance
C. Affinity is only relevant for antagonists; intrinsic activity only for agonists
D. Affinity and intrinsic activity are synonymous terms
Correct Answer: A. Affinity is the ability to bind a receptor; intrinsic activity is the ability to
activate it
Rationale: Affinity refers to the strength of drug-receptor binding, while intrinsic activity
(efficacy) describes the drug's ability to produce a response after binding. A full agonist has both
high affinity and high intrinsic activity. An antagonist has affinity but zero intrinsic activity. Partial
agonists have affinity but lower intrinsic activity than full agonists.
3|Page
, Q6. A patient taking warfarin (a CYP2C9 substrate) is prescribed amiodarone (a CYP2C9
inhibitor). What is the expected clinical consequence?
A. Decreased warfarin effect
B. Increased risk of bleeding
C. No significant interaction
D. Warfarin toxicity is unlikely
Correct Answer: B. Increased risk of bleeding
Rationale: Amiodarone inhibits CYP2C9, which metabolizes warfarin. Inhibition of this enzyme
reduces warfarin metabolism, leading to increased plasma warfarin concentrations and elevated
INR. This significantly increases bleeding risk. The warfarin dose would typically need to be reduced.
Q7. Which route of administration completely bypasses first-pass metabolism?
A. Oral
B. Rectal
C. Sublingual
D. Enteral
Correct Answer: C. Sublingual
Rationale: Sublingual administration allows drugs to be absorbed directly into the systemic
circulation through the venous drainage of the oral mucosa, bypassing the portal circulation and
hepatic first-pass metabolism. Oral and enteral routes are subject to first-pass effects. Rectal
absorption is partially subject to first-pass metabolism.
Q8. A drug that binds to a receptor and produces a submaximal response even at full receptor
occupancy is classified as:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B. Partial agonist
Rationale: A partial agonist has affinity for the receptor but lower intrinsic activity than a full
agonist, producing a submaximal response even when all receptors are occupied. A full agonist
produces maximal response. An antagonist produces no response. An inverse agonist produces
effects opposite to those of an agonist.
Q9. A patient is a CYP2D6 poor metabolizer. How would this affect codeine analgesia?
A. Enhanced analgesia
B. No analgesia
4|Page
